Search

Your search keyword '"Giannini, Edoardo G"' showing total 930 results
Start Over Author "Giannini, Edoardo G"
930 results on '"Giannini, Edoardo G"'

1. Diagnostic delay in achalasia

Author

Pasta, Andrea, Calabrese, Francesco, Ghezzi, Andrea, Savarino, Edoardo V., Savarino, Vincenzo, Zentilin, Patrizia, Furnari, Manuele, Bodini, Giorgia, Giannini, Edoardo G., and Marabotto, Elisa

Published
2024
Full Text
View/download PDF

2. Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care

Author

Stefanini, Benedetta, Bucci, Laura, Santi, Valentina, Reggidori, Nicola, Lani, Lorenzo, Granito, Alessandro, Pelizzaro, Filippo, Cabibbo, Giuseppe, Di Marco, Mariella, Ghittoni, Giorgia, Campani, Claudia, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Giannini, Edoardo G., Biasini, Elisabetta, Saitta, Carlo, Magalotti, Donatella, Sangiovanni, Angelo, Guarino, Maria, Gasbarrini, Antonio, Rapaccini, Gian Ludovico, Masotto, Alberto, Sacco, Rodolfo, Vidili, Gianpaolo, Mega, Andrea, Azzaroli, Francesco, Nardone, Gerardo, Brandi, Giovanni, Sabbioni, Simone, Vitale, Alessandro, and Trevisani, Franco

Published
2024
Full Text
View/download PDF

3. Expert opinion on bleeding risk from invasive procedures in cirrhosis

Author

Alix Riescher-Tuczkiewicz, Stephen H. Caldwell, Patrick S. Kamath, Erica Villa, Pierre-Emmanuel Rautou, Afdhal Nezam H, Ageno Walter, Bianchini Marcello, Blasi Annabel, Caldwell Stephen H, Callaway Mark, Cardenas Andres, Darwish Murad Sarwa, De Gottardi Andrea, De Pietri Lesley, De Raucourt Emmanuelle, Dell'Era Alessandra, Denys Alban, Elkrief Laure, Garcia-Pagan Juan-Carlos, Garcia-Tsao Guadalupe, Gatt Alexander, Giannini Edoardo G, Golfieri Rita, Greenberg Charles S, Hernández-Gea Virginia, Heydtmann Mathis, Intagliata Nicolas M, Kamath Patrick S, Lester Will, Magnusson Maria, Neuberger James, Northup Patrick G, O'Leary Jacqueline G, Patton Heather, Peck-Radosavljevic Markus, Pillai Anjana, Plessier Aurélie, Rautou Pierre-Emmanuel, Ripoll Cristina, Roberts Lara N, Sarwar Ammar, Senzolo Marco, Shukla Akash, Simioni Paolo, Simonetto Douglas A, Singal Ashwani K, Soto Robin, Stine Jonathan G, Tapper Elliot B, Thabut Dominique, Thachil Jecko, Tomescu Dana, Tripathi Dhiraj, Tsochatzis Emmanuel A, Villa Erica, and Valla Dominique

Subjects
haemorrhage, coagulation, haemostasis, biopsy, anticoagulant, procedural related bleeding, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Background & Aims: Despite several recent international guidelines, no consensus exists on the bleeding risk nor haemostatic parameter thresholds that define the safety of invasive procedures in patients with cirrhosis. The aim of this study was to establish a position paper on the bleeding risk associated with invasive procedures in patients with cirrhosis among the experts involved in various guidelines. Methods: All experts involved in recent guidelines on the management of invasive procedures in patients with cirrhosis were invited to classify 80 procedures as ''high risk'' or ''low risk'' with respect to bleeding. Procedures were considered high risk when the estimated risk of major bleeding was 1.5% or more, or when even minor bleeding might lead to significant morbidity or death. The experts were also asked to choose safety thresholds for laboratory test values at which elective invasive procedures could be safely performed. The predetermined threshold considered as “consensus” was ≥75% agreement. Results: Fifty-two experts participated in the study. Out of 80 procedures, a consensus opinion was reached for 52 procedures (65%): 17 procedures were classified as “high risk”, primarily interventional endoscopic procedures, percutaneous organ biopsies, or procedures involving the central nervous system; and 35 as “low risk”, primarily “diagnostic” procedures. The lowest platelet counts at which performance of a low-risk procedure or a high-risk procedure/surgery were deemed acceptable were 30 × 109/L and 50 × 109/L, respectively. Experts did not believe that international normalised ratio should be considered before performing low-risk procedures; 71% also indicated that it should not be considered before performing high-risk procedures. Conclusions: This experience-based classification may be helpful to refine future study designs and to guide clinical decision making regarding invasive procedures in patients with cirrhosis. Impact and implications: Several risk classifications and management guidelines for invasive procedures in patients with cirrhosis have been proposed, but with conflicting recommendations. By providing a position paper, based on the opinion of a broad panel of experts, on the bleeding risk associated with 52 invasive procedures in patients with cirrhosis, this survey will help to provide a framework for future study design. The consensus on platelet count, international normalised ratio, fibrinogen and activated partial thromboplastin time identified in this survey will inform physicians regarding the laboratory test values considered acceptable by the experts prior to the performance of an elective invasive procedure in patients with cirrhosis.

Published
2024
Full Text
View/download PDF

6. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs

Author

Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Benevento, Francesca, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Allegrini, Gloria, Cammà, Calogero, Cabibbo, Giuseppe, Giacchetto, Carmelo Marco, Giuffrida, Paolo, Grassini, Maria Vittoria, Grova, Mauro, Rancatore, Gabriele, Stornello, Caterina, Adotti, Valentina, Cavoli, Tancredi Li, Marra, Fabio, Rosi, Martina, Bevilacqua, Vittoria, Borghi, Alberto, Napoli, Lucia, Conti, Fabio, Frassineti, G.L., Migliano, Maria Teresa, de Matthaeis, Nicoletta, Ponziani, Francesca Romana, Missale, Gabriele, Olivani, Andrea, Capasso, Mario, Cossiga, Valentina, Guarino, Maria, Marina Cela, Ester, Facciorusso, Antonio, Graziosi, Camilla, Lauria, Valentina, Pelecca, Giorgio, Schirripa, Marta, Chegai, Fabrizio, Raso, Armando, Bozzi, Alessio, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Dajti, Elton, Ravaioli, Federico, Plaz Torres, Maria Corina, Pieri, Giulia, Oliveri, Filippo, Ricco, Gabriele, Romagnoli, Veronica, Inno, Alessandro, Marchetti, Fabiana, Coccoli, Pietro, Malerba, Antonio, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Reggidori, Nicola, Bucci, Laura, Santi, Valentina, Stefanini, Benedetta, Lani, Lorenzo, Rampoldi, Davide, Ghittoni, Giorgia, Farinati, Fabio, Masotto, Alberto, Stefanini, Bernardo, Mega, Andrea, Biasini, Elisabetta, Foschi, Francesco Giuseppe, Svegliati-Baroni, Gianluca, Sangiovanni, Angelo, Campani, Claudia, Raimondo, Giovanni, Vidili, Gianpaolo, Gasbarrini, Antonio, Celsa, Ciro, Di Marco, Mariella, Giannini, Edoardo G., Sacco, Rodolfo, Brunetto, Maurizia Rossana, Azzaroli, Francesco, Magalotti, Donatella, Morisco, Filomena, Rapaccini, Gian Ludovico, Nardone, Gerardo, Vitale, Alessandro, and Trevisani, Franco

Published
2023
Full Text
View/download PDF

7. Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma

Author

Pinato, David J., Kaneko, Takahiro, D’Alessio, Antonio, Forner, Alejandro, Fessas, Petros, Minguez, Beatriz, Giannini, Edoardo G., Grillo, Federica, Díaz, Alba, Mauri, Francesco A., Fulgenzi, Claudia A.M., Dalla Pria, Alessia, Goldin, Robert D., Pieri, Giulia, Toniutto, Pierluigi, Avellini, Claudio, Plaz Torres, Maria Corina, Akarca, Ayse U., Marafioti, Teresa, Bhoori, Sherrie, Miró, Jose María, Bower, Mark, Bräu, Norbert, and Mazzaferro, Vincenzo

Published
2023
Full Text
View/download PDF

8. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept

Author

Baccarani, Umberto, Brancaccio, Giuseppina, Cozzolongo, Raffaele, Cucchetti, Alessandro, De Matthaeis, Nicoletta, Di Sandro, Stefano, Famularo, Simone, Finotti, Michele, Foschi, Francesco G, Ghinolfi, Davide, Guarracino, Marco, Gruttadauria, Salvatore, Guarino, Maria, Kostandini, Alba, Lenci, Ilaria, Levi Sandri, Giovanni B, Manzia, Tommaso M, Marasco, Giovanni, Masarone, Mario, Mazzarelli, Chiara, Melandro, Fabio, Miele, Luca, Morisco, Filomena, Nicolini, Daniele, Pagano, Duilio, Pelizzaro, Filippo, Pieri, Giulia, Piscaglia, Fabio, Plaz Torres, Maria Corina, Pravisani, Riccardo, Rendina, Maria, Romano, Fabrizio, Russo, Francesco P, Sacco, Rodolfo, Sangiovanni, Angelo, Sposito, Carlo, Tortora, Raffaella, Tovoli, Francesco, Viganò, Mauro, Violi, Paola, Vitale, Alessandro, Cabibbo, Giuseppe, Iavarone, Massimo, Viganò, Luca, Pinato, David J, Ponziani, Francesca Romana, Lai, Quirino, Casadei-Gardini, Andrea, Celsa, Ciro, Galati, Giovanni, Gambato, Martina, Crocetti, Laura, Renzulli, Matteo, Giannini, Edoardo G, Farinati, Fabio, Trevisani, Franco, and Cillo, Umberto

Published
2023
Full Text
View/download PDF

10. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma

Author

Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Benevento, Francesca, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Bertellini, Federica, Farinati, Fabio, Palano, Giorgio, Pelizzaro, Filippo, Penzo, Barbara, Pinto, Elisa, Allegrini, Gloria, Cammà, Calogero, Celsa, Ciro, Giuffrida, Paolo, Stornello, Caterina, Grova, Mauro, Giacchetto, Carmelo Marco, Rancatore, Gabriele, Grassini, Maria Vittoria, Adotti, Valentina, Gitto, Stefano, Marra, Fabio, Rosi, Martina, Bevilacqua, Vittoria, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Napoli, Lucia, Domenicali, Marco, Migliano, Maria Teresa, de Matthaeis, Nicoletta, Ponziani, Francesca Romana, Olivani, Andrea, Missale, Gabriele, Cossiga, Valentina, Capasso, Mario, Morisco, Filomena, Cela, Ester Marina, Facciorusso, Antonio, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Dajti, Elton, Ravaioli, Federico, Oliveri, Filippo, Ricco, Gabriele, Romagnoli, Veronica, Inno, Alessandro, Marchetti, Fabiana, Coccoli, Pietro, Malerba, Antonio, Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Giannini, Edoardo G., Pieri, Giulia, Labanca, Sara, Plaz Torres, Maria Corina, Gasbarrini, Antonio, Biasini, Elisabetta, Campani, Claudia, Cazzagon, Nora, Foschi, Francesco Giuseppe, Mega, Andrea, Masotto, Alberto, Raimondo, Giovanni, Rapaccini, Gian Ludovico, Sacco, Rodolfo, Caturelli, Eugenio, Guarino, Maria, Tovoli, Francesco, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Nardone, Gerardo, Svegliati-Baroni, Gianluca, Magalotti, Donatella, Azzaroli, Francesco, Cabibbo, Giuseppe, Di Marco, Maria, Sangiovanni, Angelo, and Trevisani, Franco

Published
2022
Full Text
View/download PDF

11. Clopidogrel-Induced Eosinophilic Colitis

Author

Djahandideh Sheijani, Shirin, Calabrese, Francesco, Pasta, Andrea, Marabotto, Elisa, Bodini, Giorgia, Furnari, Manuele, Grillo, Federica, Mastracci, Luca, Savarino, Edoardo V., Savarino, Vincenzo, and Giannini, Edoardo G.

Published
2023
Full Text
View/download PDF

12. Esophageal motor disorders across ages: A retrospective multicentric analysis.

Author

Pasta, Andrea, Facchini, Chiara, Calabrese, Francesco, Bodini, Giorgia, De Bortoli, Nicola, Furnari, Manuele, Mari, Amir, Savarino, Edoardo V., Savarino, Vincenzo, Visaggi, Pierfrancesco, Zentilin, Patrizia, Giannini, Edoardo G., and Marabotto, Elisa

Subjects
MEDICAL information storage & retrieval systems, MANOMETERS, ESOPHAGEAL motility disorders, AGE distribution, GASTROINTESTINAL system, RETROSPECTIVE studies, DESCRIPTIVE statistics, MULTIVARIATE analysis, CLASSIFICATION, AGING, RESEARCH, ELECTRONIC health records, SOCIODEMOGRAPHIC factors
Abstract

Background: Age‐related changes in the gastrointestinal system are common and may be influenced by physiological aging processes. To date, a comprehensive analysis of esophageal motor disorders in patients belonging to various age groups has not been adequately reported. Methods: We conducted a retrospective assessment of high‐resolution manometry (HRM) studies in a multicenter setting. HRM parameters were evaluated according to the Chicago Classification version 4.0. Epidemiological, demographic, clinical data, and main manometric parameters, were collected at the time of the examination. Age groups were categorized as early adulthood (<35 years), early middle‐age (35–49 years), late middle‐age (50–64 years), and late adulthood (≥65 years). Results: Overall, 1341 patients (632, 47.0% male) were included with a median age of 55 years. Late adulthood patients reported more frequently dysphagia (35.2%) than early adulthood patients (24.0%, p = 0.035), early middle‐age patients (21.0%, p < 0.0001), and late middle‐aged patients (22.7%, p < 0.0001). Esophagogastric junction outflow obstruction was more prevalent in late adulthood (16.7%) than in early adulthood (6.1%, p = 0.003), and in early middle‐age (8.1%, p = 0.001). Patients with normal esophageal motility were significantly younger (52.0 years) than patients with hypercontractile esophagus (61.5 years), type III achalasia (59.6 years), esophagogastric junction outflow obstruction (59.4 years), absent contractility (57.2 years), and distal esophageal spasm (57.0 years), in multivariate model (p < 0.0001). Conclusion: The rate of esophageal motor disorders is higher in older patients, in particular esophagogastric junction outflow obstruction and hypercontractile esophagus. Future prospective studies are necessary to confirm our results and to find tailored strategies to improve clinical outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Editorial: Diagnosis of GERD in patients with extra‐oesophageal symptoms—still a long way to go… Authors' reply'

Author

Calabrese, Francesco, primary, Pasta, Andrea, additional, Bodini, Giorgia, additional, Furnari, Manuele, additional, Zentilin, Patrizia, additional, Giannini, Edoardo G., additional, Maniero, Daria, additional, Casa, Domenico Della, additional, Cataudella, Giovanni, additional, Frazzoni, Marzio, additional, Penagini, Roberto, additional, Elena, Arsiè, additional, De Bortoli, Nicola, additional, Visaggi, Pierfrancesco, additional, Savarino, Vincenzo, additional, Savarino, Edoardo, additional, and Marabotto, Elisa, additional

Published
2024
Full Text
View/download PDF

15. Applying Lyon consensus criteria in the work‐up of patients with extra‐oesophageal symptoms – A multicentre retrospective study

Author

Calabrese, Francesco, primary, Pasta, Andrea, additional, Bodini, Giorgia, additional, Furnari, Manuele, additional, Zentilin, Patrizia, additional, Giannini, Edoardo G., additional, Maniero, Daria, additional, Della Casa, Domenico, additional, Cataudella, Giovanni, additional, Frazzoni, Marzio, additional, Penagini, Roberto, additional, Elena, Arsiè, additional, de Bortoli, Nicola, additional, Visaggi, Pierfrancesco, additional, Savarino, Vincenzo, additional, Savarino, Edoardo, additional, and Marabotto, Elisa, additional

Published
2024
Full Text
View/download PDF

17. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction

Author

Fulgenzi, Claudia Angela Maria, Scheiner, Bernhard, D’Alessio, Antonio, Mehan, Aman, Manfredi, Giulia F., Celsa, Ciro, Nishida, Naoshi, Ang, Celina, Marron, Thomas U., Wu, Linda, Saeed, Anwaar, Wietharn, Brooke, Cammarota, Antonella, Pressiani, Tiziana, Pinter, Matthias, Sharma, Rohini, Cheon, Jaekyung, Huang, Yi-Hsiang, Lee, Pei-Chang, Phen, Samuel, Gampa, Anuhya, Pillai, Anjana, Napolitano, Andrea, Vivaldi, Caterina, Salani, Francesca, Masi, Gianluca, Silletta, Marianna, Lo Prinzi, Federica, Di Giacomo, Emanuela, Vincenzi, Bruno, Bettinger, Dominik, Thimme, Robert, Vogel, Arndt, Schönlein, Martin, von Felden, Johann, Schulze, Kornelius, Wege, Henning, Galle, Peter R., Pirisi, Mario, Park, Joong-Won, Kudo, Masatoshi, Rimassa, Lorenza, Singal, Amit G., El Tomb, Paul, Ulahannan, Susanna, Parisi, Alessandro, Chon, Hong Jae, Hsu, Wei-Fan, Ghittoni, Giorgia, Cammà, Calogero, Stefanini, Benedetta, Trevisani, Franco, Giannini, Edoardo G., Cortellini, Alessio, and Pinato, David James

Abstract

IMPORTANCE: Whether patients with Child-Pugh class B (CP-B) cancer with unresectable hepatocellular carcinoma (uHCC) benefit from active anticancer treatment vs best supportive care (BSC) is debated. OBJECTIVE: To evaluate the association of immune checkpoint inhibitor (ICI)–based therapies vs BSC with overall survival (OS) of patients with uHCC and CP-B liver dysfunction. DESIGN, SETTING, AND PARTICIPANTS: This retrospective, multicenter, international clinical case series examined data of patients with CP-B with uHCC who were receiving first-line ICI-based regimens from September 2017 to December 2022 whose data were extracted from an international consortium and compared with a cohort of patients with CP-B receiving BSC. Patients were treated in tertiary care centers across Europe, US, and Asia in routine clinical practice. After applying the inclusion criteria, 187 and 156 patients were left in the ICI and BSC groups, respectively. The propensity score was calculated for the following variables: age, alpha-fetoprotein levels, Child-Pugh score, extrahepatic spread, portal vein tumor thrombosis, cirrhosis, ascites, and baseline Eastern Cooperative Oncology Group performance status. EXPOSURES: Patients in the ICI group received first-line systemic therapy with either atezolizumab plus bevacizumab (A+B) (n = 141) or nivolumab (n = 46). MAIN OUTCOMES AND MEASURES: OS in the inverse probability of treatment weighting (IPTW) populations was the main outcome, and it was estimated with Kaplan-Meier method; univariable Cox regression test was used to make comparisons between the 2 groups. RESULTS: The median age was 66 (IQR, 61-72) and 73 (IQR, 66-81) years in the ICI (33 women [18%]) and BSC groups (41 women [26%]), respectively. In the IPTW populations, median OS was significantly longer in the ICI group (7.50 months; 95% CI, 5.62-11.15) compared with BSC (4.04 months; 95% CI, 3.03-5.03; hazard ratio, 0.59; 95% CI, 0.43-0.80; P &lt; .001). Multivariable analysis confirmed that ICI exposure was associated with a reduction of approximately 50% in the risk of death (hazard ratio, 0.55; 95% CI, 0.35-0.86; P &lt; .001), and the presence of portal vein tumor thrombosis, an Eastern Cooperative Oncology Group performance score of greater than 1, and alpha-fetoprotein levels of 400 ng/mL or greater were associated with increased risk of death. CONCLUSIONS AND RELEVANCE: The results of this case series provide comparative evidence of improved survival in association with ICI treatment compared with BSC in patients with uHCC with CP-B liver dysfunction.

Published
2024
Full Text
View/download PDF

18. Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma.

Author

Giannini, Edoardo G., Pasta, Andrea, Pieri, Giulia, Plaz Torres, Maria Corina, Marseglia, Mariarosaria, Pelizzaro, Filippo, Sangiovanni, Angelo, Cabibbo, Giuseppe, Ghittoni, Giorgia, Di Marco, Mariella, Foschi, Francesco Giuseppe, Guarino, Maria, Biasini, Elisabetta, Saitta, Carlo, Campani, Claudia, Svegliati-Baroni, Gianluca, Gasbarrini, Antonio, Brunetto, Maurizia Rossana, Magalotti, Donatella, and Azzaroli, Francesco

Subjects
*HEPATITIS D virus, *HEPATOCELLULAR carcinoma, *CHRONIC active hepatitis, *HEPATITIS B virus, *CANCER patients
Abstract

Background & Aims: Chronic hepatitis D virus (HDV) often leads to end-stage liver disease and hepatocellular carcinoma (HCC). Comprehensive data pertaining to large populations with HDV and HCC are missing, therefore we sought to assess the characteristics, management, and outcome of these patients, comparing them to patients with hepatitis B virus (HBV) infection. Methods: We analysed the Italian Liver Cancer database focusing on patients with positivity for HBV surface antigen and anti-HDV antibodies (HBV/HDV, n = 107) and patients with HBV infection alone (n = 588). Clinical and oncological characteristics, treatment, and survival were compared in the two groups. Results: Patients with HBV/HDV had worse liver function [Model for End-stage Liver Disease score: 11 vs. 9, p<.0001; Child-Turcotte-Pugh score: 7 vs. 5, p<.0001] than patients with HBV. HCC was more frequently diagnosed during surveillance (72.9% vs. 52.4%, p = .0002), and the oncological stage was more frequently Milan-in (67.3% vs. 52.7%, p = .005) in patients with HBV/HDV. Liver transplantation was more frequently performed in HBV/HDV than in HBV patients (36.4% vs. 9.5%), while the opposite was observed for resection (8.4% vs. 20.1%, p<.0001), and in a competing risk analysis, HBV/HDV patients had a higher probability of receiving transplantation, independently of liver function and oncological stage. A trend towards longer survival was observed in patients with HBV/HDV (50.4 vs. 44.4months, p = .106). Conclusions: In patients with HBV/HDV, HCC is diagnosed more frequently during surveillance, resulting in a less advanced cancer stage in patients with more deranged liver function than HBV alone. Patients with HBV/HDV have a heightened benefit from liver transplantation, positively influencing survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Institution of an interdisciplinary IBD centre is associated with improved healthcare utilisation.

Author

Giannini, Edoardo G., Testa, Tommaso, Grillo, Federica, Mastracci, Luca, Arrigo, Serena, Cai, Piero, Paolino, Sabrina, Burlando, Martina, Pisciotta, Livia, Formisano, Elena, Cittadini, Giuseppe, Copello, Francesco, Tuo, Sabrina, and Bodini, Giorgia

Subjects
*RHEUMATOLOGISTS, *TRANSITIONAL care, *NUTRITIONISTS, *EMERGENCY room visits
Abstract

The establishment of an interdisciplinary Inflammatory Bowel Disease (IBD) center is associated with improved healthcare utilization, according to a study published in the European Journal of Clinical Investigation. The study found that after the institution of the IBD center, hospitalizations per patient per year decreased, the number of patients on biologics increased, and there was an improvement in the total number of hospitalizations and length of hospital stay. The findings suggest that the coordinated collaboration of healthcare professionals and the implementation of specialized services can lead to better patient care and outcomes in IBD management. [Extracted from the article]

Published
2024
Full Text
View/download PDF

25. Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis.

Author

Pasta, Andrea, Calabrese, Francesco, Jaffe, Ariel, Labanca, Sara, Marenco, Simona, Pieri, Giulia, Plaz Torres, Maria Corina, Strazzabosco, Mario, and Giannini, Edoardo G.

Subjects
HEPATOCELLULAR carcinoma, ATEZOLIZUMAB, BEVACIZUMAB, ADVERSE health care events, LIVER
Abstract

Background: Safety and outcome of atezolizumab/bevacizumab in Child-Pugh B patients with hepatocellular carcinoma (HCC) have not been completely characterized. Objectives: In this study, we aimed at addressing safety and efficacy of atezolizumab/bevacizumab in Child-Pugh B patients by reviewing the available data and analyzing them by meta-analysis. Methods: We compared the safety and efficacy of atezolizumab/becavizumab treatment in patients with unresectable HCC and various degrees of liver dysfunction. A total of 8 retrospective, non-randomized, cohort studies were included in this meta-analysis, for a total of 1,071 Child-Pugh A and 225 Child-Pugh B patients. The albumin-bilirubin (ALBI) grade was also used to assess liver function, when available. Results: Grade ≥3 adverse events were observed in 11.8% of Child-Pugh class A and 26.8% class B patients (p = 0.0001), with an odds ratio (OR) of 0.43 (confidence interval [CI] 0.21–0.90; p = 0.02). Progression-free survival (PFS) at both 6 months (4.90 ± 2.08 vs. 4.75 ± 2.08 months; p = 0.0004) and 12 months (8.83 ± 2.32 vs. 7.26 ± 2.33 months; p = 0.002) was lower in Child-Pugh class B patients. A trend toward a higher objective response rate (ORR) was observed in Child-Pugh class A patients (219/856, 25.6%) as compared to Child-Pugh class B patients (25/138, 18.1%; p = 0.070), while the probability of obtaining an ORR was significantly greater in Child-Pugh A patients (OR 1.79, CI 1.12–2.86; p = 0.02). Median overall survival (OS) was 16.8 ± 2.0 and 6.8 ± 3.2 months in Child-Pugh A and B patients, respectively (mean difference 9.06 months, CI 7.01–11.1, p < 0.0001). Lastly, OS was longer in patients with ALBI grades 1–2 than in those with grade 3 (8.3 ± 11.4 vs. 3.3 ± 5.0 months, p = 0.0008). Conclusions: Oncological efficacy of atezolizumab/bevacizumab is moderate in Child-Pugh class B patients, and the shorter PFS and OS associated with the greater likelihood of experiencing treatment-related adverse events observed in these patients suggest great caution and individualization of treatment, possibly with the support of the ALBI grade. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)

Author

Minutolo, Roberto, Aghemo, Alessio, Chirianni, Antonio, Fabrizi, Fabrizio, Gesualdo, Loreto, Giannini, Edoardo G., Maggi, Paolo, Montinaro, Vincenzo, Paoletti, Ernesto, Persico, Marcello, Perticone, Francesco, Petta, Salvatore, Puoti, Massimo, Raimondo, Giovanni, Rendina, Maria, and Zignego, Anna Linda

Published
2018
Full Text
View/download PDF

31. Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)

Author

Minutolo, Roberto, Aghemo, Alessio, Chirianni, Antonio, Fabrizi, Fabrizio, Gesualdo, Loreto, Giannini, Edoardo G., Maggi, Paolo, Montinaro, Vincenzo, Paoletti, Ernesto, Persico, Marcello, Perticone, Francesco, Petta, Salvatore, Puoti, Massimo, Raimondo, Giovanni, Rendina, Maria, Zignego, Anna Linda, on behalf of the Italian Society of Nephrology (SIN), the Italian Association for the Study of the Liver (AISF), the Italian Society of Infectious and Tropical Disease (SIMIT), and the Italian Society of Internal Medicine (SIMI)

Published
2019
Full Text
View/download PDF

32. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs

Author

Reggidori, Nicola, primary, Bucci, Laura, additional, Santi, Valentina, additional, Stefanini, Benedetta, additional, Lani, Lorenzo, additional, Rampoldi, Davide, additional, Ghittoni, Giorgia, additional, Farinati, Fabio, additional, Masotto, Alberto, additional, Stefanini, Bernardo, additional, Mega, Andrea, additional, Biasini, Elisabetta, additional, Foschi, Francesco Giuseppe, additional, Svegliati-Baroni, Gianluca, additional, Sangiovanni, Angelo, additional, Campani, Claudia, additional, Raimondo, Giovanni, additional, Vidili, Gianpaolo, additional, Gasbarrini, Antonio, additional, Celsa, Ciro, additional, Di Marco, Mariella, additional, Giannini, Edoardo G., additional, Sacco, Rodolfo, additional, Brunetto, Maurizia Rossana, additional, Azzaroli, Francesco, additional, Magalotti, Donatella, additional, Morisco, Filomena, additional, Rapaccini, Gian Ludovico, additional, Nardone, Gerardo, additional, Vitale, Alessandro, additional, Trevisani, Franco, additional, Biselli, Maurizio, additional, Caraceni, Paolo, additional, Gramenzi, Annagiulia, additional, Benevento, Francesca, additional, Granito, Alessandro, additional, Muratori, Luca, additional, Piscaglia, Fabio, additional, Tovoli, Francesco, additional, Allegrini, Gloria, additional, Cammà, Calogero, additional, Cabibbo, Giuseppe, additional, Giacchetto, Carmelo Marco, additional, Giuffrida, Paolo, additional, Grassini, Maria Vittoria, additional, Grova, Mauro, additional, Rancatore, Gabriele, additional, Stornello, Caterina, additional, Adotti, Valentina, additional, Cavoli, Tancredi Li, additional, Marra, Fabio, additional, Rosi, Martina, additional, Bevilacqua, Vittoria, additional, Borghi, Alberto, additional, Napoli, Lucia, additional, Conti, Fabio, additional, Frassineti, G.L., additional, Migliano, Maria Teresa, additional, de Matthaeis, Nicoletta, additional, Ponziani, Francesca Romana, additional, Missale, Gabriele, additional, Olivani, Andrea, additional, Capasso, Mario, additional, Cossiga, Valentina, additional, Guarino, Maria, additional, Marina Cela, Ester, additional, Facciorusso, Antonio, additional, Graziosi, Camilla, additional, Lauria, Valentina, additional, Pelecca, Giorgio, additional, Schirripa, Marta, additional, Chegai, Fabrizio, additional, Raso, Armando, additional, Bozzi, Alessio, additional, Franzè, Maria Stella, additional, Saitta, Carlo, additional, Sauchella, Assunta, additional, Dajti, Elton, additional, Ravaioli, Federico, additional, Plaz Torres, Maria Corina, additional, Pieri, Giulia, additional, Oliveri, Filippo, additional, Ricco, Gabriele, additional, Romagnoli, Veronica, additional, Inno, Alessandro, additional, Marchetti, Fabiana, additional, Coccoli, Pietro, additional, Malerba, Antonio, additional, Cappelli, Alberta, additional, Golfieri, Rita, additional, Mosconi, Cristina, additional, and Renzulli, Matteo, additional

Published
2023
Full Text
View/download PDF

34. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study

Author

Tabone, Marco, Andreoni, Massimo, Teti, Elisabetta, Angelico, Mario, Persico, Marcello, Masarone, Mario, Chiodera, Aledssandro, Solinas, Attilio, delle Monache, Marco, Cecere, Roberto, Maria Schimizzi, Anna, Piovesan, Sara, Campagnolo, Davide, Chiara Piras, Maria, Zolfino, Teresa, Paolo Russo, Francesca, Morelli, Olivia, Sangiovanni, Vincenzo, Onofrio, Mirella, Iodice, Valentina, Izzi, Antonio, Pirisi, Massimo, Danieli, Elena, Vinci, Maria, Rizzardini, Giuliano, Fagiuoli, Stefano, Pasulo, Luisa, D'Arminio Monforte, Antonella, Zuin, Massimo, Giorgini, Alessia, Simeone, Filomena, Piali, Guido, Lo Guercio, Carmela, Federico, Alessandro, Brancaccio, Giuseppina, Marrone, Aldo, Abbati, Giuseppe, Boarini, Chiara, Borghi, Vanni, Bernabucci, Veronica, Corti, Giampaolo, Monti, Monica, Rizzetto, Mario, Martini, Silvia, Andreone, Pietro, Gianstefani, Alice, Lenzi, Marco, Verucchi, Gabriella, Toniutto, Pierluigi, Borgia, Guglielmo, Caporaso, Nicola, Morisco, Filomena, Nardone, Gaetano, Angrisani, Debora, Giacometti, Andrea, Benedetti, Antonio, Tarantino, Giuseppe, Marsetti, Fabio, Tavio, Marcello, Novara, Sergio, Antonia Santantonio, Teresa, Serviddio, Gaetano, Brunetto, Maurizia, Coco, Barbara, Angarano, Gioacchino, Milella, Michele, Barone, Michele, Di Leo, Alfredo, Ettore Sansonno, Domenico, Cacciola, Irene, Boffa, Nicola, Saracco, Giorgio, Di Biagio, Antonio, Picciotto, Antonino, de Luca, Andrea, Calvaruso, Vincenza, Corradori, Silvia, Ferrari, Carlo, Orlandini, Alessandra, Maida, Ivana, Torti, Carlo, Chessa, Luchino, Felder, Martina, Vespasiani Gentilucci, Umberto, Angeli, Paolo, Romano, Antonietta, Ludovico Rapaccini, Gian, Miele, Luca, Cima, Serena, Luisa Russo, Maria, Cozzolongo, Raffaele, Onnelli, Giovanna, D'Offizi, Giampiero, Lionetti, Raffaella, Montalbano, Marzia, Guerra, Michele, Di Perri, Giovanni, Boglione, Lucio, Capra, Franco, Carolo, Giada, Ieluzzi, Donatella, Antonini, Cinzia, Termite, Antonio, Madonia, Salvatore, Tarquini, Pierluigi, Parruti, Giustino, Vecchiet, Giacomo, Falasca, Katia, Menzaghi, Barbara, Quirino, Tiziana, Dentone, Chiara, Maria Piscaglia, Anna, Rossi, Cristina, Giordani, Maria, Fontanella, Luca, Cassola, Giovanni, Russello, Maurizio, Cristaudo, Antonio, Giacomet, Vania, Colombo, Massimo, Donato, Francesca, Durante, Emanuele, Cosco, Lucio, Marignani, Massimo, Quartini, Mariano, Memoli, Massimo, Ganga, Roberto, Ponti, Laura, Soria, Alessandro, Grazia Rumi, Maria, Gulminetti, Roberto, Maserati, Renato, Mondelli, Mario, Lazzarin, Adriano, Rita Parisi, Maria, Canovari, Benedetta, Avancini, Ivo, Pravadelli, Cecilia, Blanc, Pier, Pasquazzi, Caterina, Maria Mastroianni, Claudio, Lichtner, Myriam, Distefano, Marco, Magnani, Silvia, Paganin, Simona, Erne, Elke, Gatti, Pietro, Tundi, Paolo, Calabrese, Paolo, Gasbarrini, Antonio, Grieco, Antonio, Coppola, Nicola, Del Poggio, Paolo, Levrero, Massimo, Talliani, Gloria, Vullo, Vincenzo, Cauda, Roberto, La Monica, Silvia, Potenza, Domenico, Rizzo, Salvatore, Castelli, Francesco, Marie Pigozzi, Grazielle, Ciancio, Alessia, Romagnoli, Dante, Barchetti, Federica, Ivanovic, Jelena, Longo, Olimpia, Petraglia, Sandra, Paola Trotta, Maria, Petta, Salvatore, Marzioni, Marco, Russo, Pierluigi, Aghemo, Alessio, Alberti, Alfredo, Ascione, Antonio, Antinori, Andrea, Bruno, Raffaele, Bruno, Savino, Chirianni, Antonio, Gaeta, Giovanni Battista, Giannini, Edoardo G, Merli, Manuela, Messina, Vincenzo, Montilla, Simona, Perno, Carlo Federico, Puoti, Massimo, Raimondo, Giovanni, Rendina, Maria, Silberstein, Francesca Ceccherini, Villa, Erica, Zignego, Anna Linda, Pani, Luca, and Craxì, Antonio

Published
2017
Full Text
View/download PDF

37. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

Author

Ascione, Antonio, De Luca, Massimo, Melazzini, Mario, Montilla, Simona, Trotta, Maria Paola, Petta, Salvatore, Puoti, Massimo, Sangiovanni, Vincenzo, Messina, Vincenzo, Bruno, Savino, Izzi, Antonio, Villa, Erica, Aghemo, Alessio, Zignego, Anna Linda, Orlandini, Alessandra, Fontanella, Luca, Gasbarrini, Antonio, Marzioni, Marco, Giannini, Edoardo G., and Craxì, Antonio

Published
2018
Full Text
View/download PDF

38. Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group

Author

Vitale, Alessandro, Lai, Quirino, Farinati, Fabio, Bucci, Laura, Giannini, Edoardo G., Napoli, Lucia, Ciccarese, Francesca, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cabibbo, Giuseppe, Virdone, Roberto, Marra, Fabio, Felder, Martina, Morisco, Filomena, Benvegnù, Luisa, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Colecchia, Antonio, Bernardi, Mauro, Trevisani, Franco, Pawlik, Timothy M., and On behalf of the Italian Liver Cancer (ITA.LI.CA) group

Published
2018
Full Text
View/download PDF

41. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept

Author

Vitale, Alessandro, Cabibbo, Giuseppe, Iavarone, Massimo, Viganò, Luca, Pinato, David J, Ponziani, Francesca Romana, Lai, Quirino, Casadei-Gardini, Andrea, Celsa, Ciro, Galati, Giovanni, Gambato, Martina, Crocetti, Laura, Renzulli, Matteo, Giannini, Edoardo G, Farinati, Fabio, Trevisani, Franco, Cillo, Umberto, Miele, Luca, HCC Special Interest Group of the Italian Association for the Study of the, Liver, Ponziani, Francesca Romana (ORCID:0000-0002-5924-6238), Miele, Luca (ORCID:0000-0003-3464-0068), HCC Special Interest Group of the Italian Association for the Study of the Liver, Vitale, Alessandro, Cabibbo, Giuseppe, Iavarone, Massimo, Viganò, Luca, Pinato, David J, Ponziani, Francesca Romana, Lai, Quirino, Casadei-Gardini, Andrea, Celsa, Ciro, Galati, Giovanni, Gambato, Martina, Crocetti, Laura, Renzulli, Matteo, Giannini, Edoardo G, Farinati, Fabio, Trevisani, Franco, Cillo, Umberto, Miele, Luca, HCC Special Interest Group of the Italian Association for the Study of the, Liver, Ponziani, Francesca Romana (ORCID:0000-0002-5924-6238), Miele, Luca (ORCID:0000-0003-3464-0068), and HCC Special Interest Group of the Italian Association for the Study of the Liver

Abstract

Advances in the surgical and systemic therapeutic landscape of hepatocellular carcinoma have increased the complexity of patient management. A dynamic adaptation of the available staging-based algorithms is required to allow flexible therapeutic allocation. In particular, real-world hepatocellular carcinoma management increasingly relies on factors independent of oncological staging, including patients' frailty, comorbid burden, critical tumour location, multiple liver functional parameters, and specific technical contraindications impacting the delivery of treatment and resource availability. In this Policy Review we critically appraise how treatment allocation strictly based on pretreatment staging features has shifted towards a more personalised treatment approach, in which expert tumour boards assume a central role. We propose an evidence-based framework for hepatocellular carcinoma treatment based on the novel concept of multiparametric therapeutic hierarchy, in which different therapeutic options are ordered according to their survival benefit (ie, from surgery to systemic therapy). Moreover, we introduce the concept of converse therapeutic hierarchy, in which therapies are ordered according to their conversion abilities or adjuvant abilities (ie, from systemic therapy to surgery).

Published
2023

42. The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma

Author

Lai, Quirino, De Matthaeis, Nicoletta, Finotti, Michele, Galati, Giovanni, Marrone, Giuseppe, Melandro, Fabio, Morisco, Filomena, Nicolini, Daniele, Pravisani, Riccardo, Giannini, Edoardo G, Aglitti, A, Aliberti, C, Baccarani, U, Bhoori, S, Borzio, M, Brancaccio, G, Burra, P, Cabibbo, G, Casadei Gardini, A, Carrai, P, Cillo, U, Conti, F, Cucchetti, A, D'Ambrosio, R, Dell'Unto, C, Di Costanzi, Gg, Di Sandro, S, Foschi, Fg, Fucilli, F, Gambato, M, Gasbarrini, Antonio, Giuliante, Felice, Ghinolfi, D, Grieco, Antonio, Gruttaduria, S, Guarino, M, Kostandini, A, Iavarone, M, Lenci, I, Levi Sandri, Gb, Losito, F, Lupo, Lg, Manzia, Tm, Mazzocato, S, Mescoli, C, Miele, Luca, Muley, M, Persico, M, Plaz Torres, Mc, Pompili, Maurizio, Ponziani, Francesca Romana, Rapaccini, Gian Ludovico, Rendina, M, Renzulli, M, Rossi, Marco, Rreka, E, Russo, Fp, Sacco, R, Sangiovanni, A, Sessa, A, Simonetti, N, Sposito, C, Tortora, R, Trevisani, F, Viganò, L, Viganò, M, Villa, E, Vincenzi, V, Violi, P, Vitale, A, Gasbarrini, A (ORCID:0000-0002-7278-4823), Giuliante, F (ORCID:0000-0001-9517-8220), Grieco, A (ORCID:0000-0002-0544-8993), Miele, L (ORCID:0000-0003-3464-0068), Pompili, M (ORCID:0000-0001-6699-7980), Ponziani, FR (ORCID:0000-0002-5924-6238), Rapaccini, GL (ORCID:0000-0002-6467-857X), Rossi, M (ORCID:0000-0002-4539-5670), Lai, Quirino, De Matthaeis, Nicoletta, Finotti, Michele, Galati, Giovanni, Marrone, Giuseppe, Melandro, Fabio, Morisco, Filomena, Nicolini, Daniele, Pravisani, Riccardo, Giannini, Edoardo G, Aglitti, A, Aliberti, C, Baccarani, U, Bhoori, S, Borzio, M, Brancaccio, G, Burra, P, Cabibbo, G, Casadei Gardini, A, Carrai, P, Cillo, U, Conti, F, Cucchetti, A, D'Ambrosio, R, Dell'Unto, C, Di Costanzi, Gg, Di Sandro, S, Foschi, Fg, Fucilli, F, Gambato, M, Gasbarrini, Antonio, Giuliante, Felice, Ghinolfi, D, Grieco, Antonio, Gruttaduria, S, Guarino, M, Kostandini, A, Iavarone, M, Lenci, I, Levi Sandri, Gb, Losito, F, Lupo, Lg, Manzia, Tm, Mazzocato, S, Mescoli, C, Miele, Luca, Muley, M, Persico, M, Plaz Torres, Mc, Pompili, Maurizio, Ponziani, Francesca Romana, Rapaccini, Gian Ludovico, Rendina, M, Renzulli, M, Rossi, Marco, Rreka, E, Russo, Fp, Sacco, R, Sangiovanni, A, Sessa, A, Simonetti, N, Sposito, C, Tortora, R, Trevisani, F, Viganò, L, Viganò, M, Villa, E, Vincenzi, V, Violi, P, Vitale, A, Gasbarrini, A (ORCID:0000-0002-7278-4823), Giuliante, F (ORCID:0000-0001-9517-8220), Grieco, A (ORCID:0000-0002-0544-8993), Miele, L (ORCID:0000-0003-3464-0068), Pompili, M (ORCID:0000-0001-6699-7980), Ponziani, FR (ORCID:0000-0002-5924-6238), Rapaccini, GL (ORCID:0000-0002-6467-857X), and Rossi, M (ORCID:0000-0002-4539-5670)

Abstract

Aim To evaluate the impact of antiplatelet therapy (APT)on the incidence of hepatocellular carcinoma (HCC) and mortality following its treatment. Methods A systematic literature search was performed using PubMed and Cochrane Central Register of Controlled Trials Databases. Two HCC clinical settings were explored: (i) incidence, and (ii) death after any HCC treatment. Odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to compare the pooled data between patients who received or did not receive APT. Results A total of 20 studies were identified, of whom 15 focused on HCC incidence, including 2,685,009 patients, and five on post-treatment death, including 3281 patients. APT was associated with an overall reduced risk of HCC incidence (OR: 0.63; 95%CI = 0.51-0.79; p < 0.001) as well as of post-treatment mortality (OR: 0.54; 95%CI = 0.35-0.83; p = 0.006). Conclusions Current data suggest that APT correlated with higher HCC incidence and poor overall survival following tumour treatment.

Published
2023

43. Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference

Author

Andriulli, Angelo, Tripodi, Armando, Angeli, Paolo, Senzolo, Marco, Primignani, Massimo, Giannini, Edoardo G., Riggio, Oliviero, Colli, Agostino, Prati, Daniele, Sacerdoti, David, Merkel, Carlo, Basili, Stefania, Ferro, Domenico, Villa, Erica, Di Minno, Giovanni, Caraceni, Paolo, Marzioni, Marco, Mannucci, Pier Mannuccio, Violi, Francesco, Piscaglia, Fabio, Calvaruso, Vincenza, De Pietri, Lesley, Falcone, Marco, Feltracco, Paolo, Grandone, Elvira, La Mura, Vincenzo, Licata, Anna, Lucidi, Cristina, Maimone, Sergio, Marietta, Marco, Morisco, Filomena, Napoleone, Laura, Piano, Salvatore, Raparelli, Valeria, Rebulla, Paolo, Ribero, Dario, Sartori, Maria Teresa, Scalera, Antonella, Schepis, Filippo, Siciliano, Massimo, Baroni, Gianluca Svegliati, Tufano, Antonella, Vitale, Alessandro, and Zuin, Massimo

Published
2016
Full Text
View/download PDF

45. Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma

Author

Cucchetti, Alessandro, Giannini, Edoardo G., Mosconi, Cristina, Plaz Torres, Maria Corina, Pieri, Giulia, Farinati, Fabio, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Sacco, Rodolfo, Cabibbo, Giuseppe, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Sansone, Vito, Zoli, Marco, Azzaroli, Francesco, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Rampoldi, Davide, Reggidori, Nicola, Santi, Valentina, Stefanini, Benedetta, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Magalotti, Donatella, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Renzulli, Matteo, Pelizzaro, Filippo, Penzo, Barbara, Marina Cela, Ester, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Biasini, Elisabetta, Olivani, Andrea, Inno, Alessandro, Marchetti, Fabiana, Celsa, Ciro, Grova, Mauro, Stornello, Caterina, Busacca, Anita, Cammà, Calogero, Maria Rizzo, Giacomo Emanuele, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Napoli, Lucia, Bevilacqua, Vittoria, Berardinelli, Dante, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Marra, Fabio, Di Bonaventura, Chiara, Gitto, Stefano, Adotti, Valentina, Coccoli, Pietro, Malerba, Antonio, Capasso, Mario, Morisco, Filomena, Oliveri, Filippo, Romagnoli, Veronica, Cucchetti, Alessandro, Giannini, Edoardo G., Mosconi, Cristina, Plaz Torres, Maria Corina, Pieri, Giulia, Farinati, Fabio, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Sacco, Rodolfo, Cabibbo, Giuseppe, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Sansone, Vito, Zoli, Marco, Azzaroli, Francesco, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Rampoldi, Davide, Reggidori, Nicola, Santi, Valentina, Stefanini, Benedetta, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Magalotti, Donatella, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Renzulli, Matteo, Pelizzaro, Filippo, Penzo, Barbara, Marina Cela, Ester, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Biasini, Elisabetta, Olivani, Andrea, Inno, Alessandro, Marchetti, Fabiana, Celsa, Ciro, Grova, Mauro, Stornello, Caterina, Busacca, Anita, Cammà, Calogero, Maria Rizzo, Giacomo Emanuele, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Napoli, Lucia, Bevilacqua, Vittoria, Berardinelli, Dante, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Marra, Fabio, Di Bonaventura, Chiara, Gitto, Stefano, Adotti, Valentina, Coccoli, Pietro, Malerba, Antonio, Capasso, Mario, Morisco, Filomena, Oliveri, Filippo, and Romagnoli, Veronica

Subjects
Liver Cancer, Pre-TACE-Predict model, medicine.medical_specialty, business.industry, Trans-arterial chemoembolization, Pharmaceutical Science, hepatocellular carcinoma, medicine.disease, Gastroenterology, Complementary and alternative medicine, Internal medicine, Hepatocellular carcinoma, medicine, Pharmacology (medical), Trans arterial chemoembolization, business
Abstract

Background & Aims The Pre-TACE-Predict model was devised to assess prognosis of patients treated with trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). However, before entering clinical practice, a model should demonstrate that it performs a useful role. Methods We performed an independent external validation of the Pre-TACE model in a cohort that differs in setting and time period from the one that generated the original model. Data from 826 patients treated with TACE for naïve HCC (2008-2018) were used to assess calibration and discrimination of the Pre-TACE-Predict model. Results The four risk-categories identified by the Pre-TACE-Predict model had gradient monotonicity, with median survivals of 52.0, 36.2, 29.9, and 14.1 months respectively. However, predicted survivals systematically underestimated observed survivals (R2: 0.667). A recalibration was adopted maintaining fixed the prognostic index and modifying the baseline survival function. This resulted in an almost perfect calibration (R2: 0.995) in all the four risk categories. Cox regressions showed that aetiology and macrovascular invasion, included in the Pre-TACE-Predict model, had no prognostic impact in the present study population, and that coefficients for tumour size and multiplicity were overestimated. The c-index was similar to that of the m-HAP-III, but higher than those of HAP, m-HAP-II and the six-and-twelve models. Conclusions The recalibration of Pre-TACE-Predict model improved the estimation of survival probabilities of HCC patients treated with TACE. The highest discriminatory ability of the Pre-TACE-model in comparison to other available models, together with risk stratification and recalibration, makes it the best prognostic tool currently available for these patients.

Published
2021

48. Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis

Author

Sacco, Rodolfo, primary, Ramai, Daryl, additional, Tortora, Raffaella, additional, di Costanzo, Giovan Giuseppe, additional, Burlone, Michela Emma, additional, Pirisi, Mario, additional, Federico, Piera, additional, Daniele, Bruno, additional, Silletta, Marianna, additional, Gallo, Paolo, additional, Cocuzza, Caterina, additional, Russello, Maurizio, additional, Cabibbo, Giuseppe, additional, Rancatore, Gabriele, additional, Cesario, Silvia, additional, Masi, Gianluca, additional, Marzi, Luca, additional, Mega, Andrea, additional, Granito, Alessandro, additional, Pieri, Giulia, additional, Giannini, Edoardo G., additional, Paolillo, Rosa, additional, Gadaleta-Caldarola, Gennaro, additional, Dadduzio, Vincenzo, additional, Giordano, Guido, additional, Giacomelli, Luca, additional, Papa, Simonetta, additional, Renzulli, Matteo, additional, Maida, Marcello, additional, Ghidini, Michele, additional, Borzio, Mauro, additional, and Facciorusso, Antonio, additional

Published
2023
Full Text
View/download PDF

50. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study

Author

Vitale, Alessandro, Burra, Patrizia, Frigo, Anna Chiara, Trevisani, Franco, Farinati, Fabio, Spolverato, Gaya, Volk, Michael, Giannini, Edoardo G., Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Mariella, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Gasbarrini, Antonio, Sacco, Rodolfo, Foschi, Francesco Giuseppe, Missale, Gabriele, Morisco, Filomena, Svegliati Baroni, Gianluca, Virdone, Roberto, and Cillo, Umberto

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results